Company: RCUS
Filing Date: 2025-11-03
Form Type: 8-K
Source: 0001193125-25-262589
Chunk: 0

Company: Arcus Biosciences, Inc.
Filing Date: 2025-11-03
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

On October 30, 2025, Arcus Biosciences, Inc. (the “ Company”) entered into an underwriting agreement (the “ Underwriting Agreement”) with Leerink Partners LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters”), relating to the public offering, issuance and sale of 13,700,000 shares of the Company’s common stock (“ Common Stock”), at the public offering price of $18.25 per share (the “ Offering”). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase up to an additional 2,055,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions (the “Underwriters’ Option”). The Underwriters agreed to purchase the shares of Common Stock from the Company at a price of $17.155 per share.